ALX148: Ph I AT148001 started

Alexo began the 2-part, open-label, dose-escalation, U.S. Phase I AT148001 trial to evaluate ALX148 in about 110 patients. Part 1 will evaluate ascending doses of ALX148 given alone weekly or every 2 ...